Press release

The power of connecting patents and clinical trials: leveraging competitive intelligence for pharmaceutical companies

Posted on by

SOPHIA ANTIPOLIS, France – October 10, 2023 │ In the pharmaceutical industry, patents are crucial for companies developing new therapies and conducting clinical trials to assess their effectiveness. Given the time-consuming and expensive process of developing a new drug, patents provide legal protection to the company, guaranteeing a period of exclusivity to sell the medication[…]

Is allogeneic CAR treatment the next evolution of CAR technology?

Posted on by

SOPHIA ANTIPOLIS, France – September 28, 2023 │Since the FDA approval of two CAR-T cell therapies in 2017, CAR therapy has gained a big interest. Indeed, KYMRIAH™ (tisagenlecleucel) from Novartis and YESCARTA™ (Axicabtagene Ciloleucel) from Kite Pharma, a Gilead company, received the first FDA approval for chimeric antigen receptor (CAR) therapy in 2017. These two[…]

Q2 2023 Therapeutic mRNA Patent Monitor Report: LNP still best-in-class delivery & boost for Self-Amplifying mRNA design

Posted on by

SOPHIA ANTIPOLIS, France – August 31, 2023 │The quarterly report for the Q2 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on current dynamics in mRNA design. Exploring the dynamic activity of therapeutic mRNA innovations Therapeutic mRNA,[…]